BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18426086)

  • 1. Aberrant FHIT transcripts in human colorectal cancers.
    Lee SH; Lee SH
    Res Commun Mol Pathol Pharmacol; 2005; 117-118():153-65. PubMed ID: 18426086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant splicing of FHIT transcripts in human gastric cancer cell lines.
    Lee SH; Kim HY; Kim TJ; Park HK; Kim WH; Woo KM; Cho MH
    Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):39-49. PubMed ID: 15080495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the fragile histidine triad gene in normal rat tissues and human kidney cancer cell lines.
    Lee SH; Kim TJ; Kim HY; Kim JG; Park MK; Woo KM; Kim SH; Hwang KY; Nam HS; Min YK; Cho MH
    Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):145-57. PubMed ID: 15080505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
    Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
    Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
    Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
    BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of the FHIT gene in human colorectal cancer is independent of high-risk HPV infection.
    Yu HG; Shun LB; Luo HS; Huang H; Yu BP; Yu JP; Meier JJ; Schrader H; Bastian A; Schmitz F; Schmidt WE
    Int J Colorectal Dis; 2002 Nov; 17(6):396-401. PubMed ID: 12355215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
    Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
    Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
    Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
    Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas.
    Bugert P; Wilhelm M; Kovacs G
    Genes Chromosomes Cancer; 1997 Sep; 20(1):9-15. PubMed ID: 9290948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Abnormal expression of the FHIT gene in human primary gastrointestinal cancers].
    Duan XM; Zhang GY; Wu ES
    Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):331-3. PubMed ID: 12205991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
    Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
    J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
    Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
    Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis.
    Gramantieri L; Chieco P; Di Tomaso M; Masi L; Piscaglia F; Brillanti S; Gaiani S; Valgimigli M; Mazziotti A; Bolondi L
    Clin Cancer Res; 1999 Nov; 5(11):3468-75. PubMed ID: 10589760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma.
    Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen RL; Gao JX; He G
    Ann Clin Lab Sci; 2010; 40(3):267-72. PubMed ID: 20689140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.
    Wierzbicki PM; Adrych K; Kartanowicz D; Dobrowolski S; Stanislawowski M; Chybicki J; Godlewski J; Korybalski B; Smoczynski M; Kmiec Z
    J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():63-70. PubMed ID: 20083853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma.
    Kameoka Y; Tagawa H; Tsuzuki S; Karnan S; Ota A; Suguro M; Suzuki R; Yamaguchi M; Morishima Y; Nakamura S; Seto M
    Oncogene; 2004 Dec; 23(56):9148-54. PubMed ID: 15480422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas.
    Lee SH; Kim WH; Kim HK; Woo KM; Nam HS; Kim HS; Kim JG; Cho MH
    Biochem Biophys Res Commun; 2001 Jun; 284(3):850-5. PubMed ID: 11396980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines.
    Mao L; Fan YH; Lotan R; Hong WK
    Cancer Res; 1996 Nov; 56(22):5128-31. PubMed ID: 8912845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of the common fragile site FRA3B does not affect FHIT expression.
    Michael D; Rajewsky MF
    Oncogene; 2001 Mar; 20(14):1798-801. PubMed ID: 11313927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.